Specializing In
- Antiretroviral Therapy (ART)
- Chlamydia
- Gonorrhea
- HIV and AIDS
- Infectious Diseases
- LGV (Lymphogranuloma Venereum)
- Sexually Transmitted Infections (STIs)
- Syphilis
Biography
My ÌÇÐÄ´«Ã½ focuses on antiretroviral therapy and complications of HIV including immune reconstitution inflammatory disease, osteoporosis, and cardiovascular disease.
View Full Biography
Professional Summary
Education & Certifications
- Board Certification: American Board of Internal Medicine, Infectious Disease (2008)
- Residency: University of Washington Medical Center Dept of Medicine (2003) WA
- Internship: University of Washington Medical Center Dept of Medicine (2001) WA
-
- Medical Education: University of California at San Francisco School of Medicine (2000) CA
- Fellowship, Stanford University Infectious Dseases (2010)
Publications
-
Virologic Response to Lopinavir-Ritonavir-Based Antiretroviral Regimens in a Multicenter International Clinical Cohort: Comparison of Genotypic Interpretation Scores
Grant, P., Wong, E. C., Rode, R., Shafer, R., De Luca, A., Nadler, J., … Zolopa, A. (2008). Virologic Response to Lopinavir-Ritonavir-Based Antiretroviral Regimens in a Multicenter International Clinical Cohort: Comparison of Genotypic Interpretation Scores. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 52(11), 4050–56. -
Integrase inhibitors: a clinical review of raltegravir and elvitegravir.
Grant, P., & Zolopa, A. (2008). Integrase inhibitors: a clinical review of raltegravir and elvitegravir. Journal of HIV Therapy, 13(2), 36–39. -
Maintaining Reduced Viral Fitness and CD4 Response in HIV-Infected Patients with Viremia Receiving a Boosted Protease Inhibitor
Grant, P., Taylor, J., Cain, P., Short, W., Gallant, J., Farthing, C., … Zolopa, A. (2009). Maintaining Reduced Viral Fitness and CD4 Response in HIV-Infected Patients with Viremia Receiving a Boosted Protease Inhibitor. CLINICAL INFECTIOUS DISEASES, 48(5), 680–82. -
-
Initiation of antiretroviral therapy in the hospitalized patient with an acute AIDS-related opportunistic infection and other conditions: no time to lose.
Grant, P., & Zolopa, A. (2009). Initiation of antiretroviral therapy in the hospitalized patient with an acute AIDS-related opportunistic infection and other conditions: no time to lose. Current HIV/AIDS Reports, 6(2), 63–67. -
Switch from enfuvirtide to raltegravir in virologically suppressed HIV-1 infected patients: Effects on level of residual viremia and quality of life
Grant, P. M., Palmer, S., Bendavid, E., Talbot, A., Slamowitz, D. C., Cain, P., … Zolopa, A. R. (2009). Switch from enfuvirtide to raltegravir in virologically suppressed HIV-1 infected patients: Effects on level of residual viremia and quality of life. JOURNAL OF CLINICAL VIROLOGY, 46(4), 305–8. -
The use of resistance testing in the management of HIV-1-infected patients
Grant, P. M., & Zolopa, A. R. (2009). The use of resistance testing in the management of HIV-1-infected patients. CURRENT OPINION IN HIV AND AIDS, 4(6), 474–80. -
International Cohort Analysis of the Antiviral Activities of Zidovudine and Tenofovir in the Presence of the K65R Mutation in Reverse Transcriptase
Grant, P. M., Taylor, J., Nevins, A. B., Calvez, V., Marcelin, A.-G., Wirden, M., & Zolopa, A. R. (2010). International Cohort Analysis of the Antiviral Activities of Zidovudine and Tenofovir in the Presence of the K65R Mutation in Reverse Transcriptase. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 54(4), 1520–25. -
Predicting Tipranavir and Darunavir Resistance Using Genotypic, Phenotypic, and Virtual Phenotypic Resistance Patterns: an Independent Cohort Analysis of Clinical Isolates Highly Resistant to All Other Protease Inhibitors
Talbot, A., Grant, P., Taylor, J., Baril, J.-G., Liu, T. F., Charest, H., … Zolopa, A. (2010). Predicting Tipranavir and Darunavir Resistance Using Genotypic, Phenotypic, and Virtual Phenotypic Resistance Patterns: an Independent Cohort Analysis of Clinical Isolates Highly Resistant to All Other Protease Inhibitors. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 54(6), 2473–2479. -
Risk Factor Analyses for Immune Reconstitution Inflammatory Syndrome in a Randomized Study of Early vs. Deferred ART during an Opportunistic Infection
Grant, P. M., Komarow, L., Andersen, J., Sereti, I., Pahwa, S., Lederman, M. M., … Zolopa, A. (2010). Risk Factor Analyses for Immune Reconstitution Inflammatory Syndrome in a Randomized Study of Early vs. Deferred ART during an Opportunistic Infection. PLOS ONE, 5(7). -
Optimal antiretroviral therapy: HIV-1 treatment strategies to avoid and overcome drug resistance
Grant, P. M., & Zolopa, A. R. (2010). Optimal antiretroviral therapy: HIV-1 treatment strategies to avoid and overcome drug resistance. CURRENT OPINION IN INVESTIGATIONAL DRUGS, 11(8), 901–10. -
Concerns Regarding a Randomized Study of the Timing of Antiretroviral Therapy in Zimbabweans with AIDS and Acute Cryptococcal Meningitis
Grant, P. M., Aberg, J. A., & Zolopa, A. R. (2010). Concerns Regarding a Randomized Study of the Timing of Antiretroviral Therapy in Zimbabweans with AIDS and Acute Cryptococcal Meningitis. CLINICAL INFECTIOUS DISEASES, 51(8), 984–985. -
Cost-effectiveness of antiretroviral regimens in the World Health Organization's treatment guidelines: a South African analysis
Bendavid, E., Grant, P., Talbot, A., Owens, D. K., & Zolopa, A. (2011). Cost-effectiveness of antiretroviral regimens in the World Health Organization's treatment guidelines: a South African analysis. AIDS, 25(2), 211–20. -
When to start ART in the setting of acute AIDS-related opportunistic infections: the time is now!
Grant, P. M., & Zolopa, A. R. (2012). When to start ART in the setting of acute AIDS-related opportunistic infections: the time is now! Current HIV/AIDS Reports, 9(3), 251–58. -
Elevated Interleukin 8 and T-Helper 1 and T-Helper 17 Cytokine Levels Prior to Antiretroviral Therapy in Participants Who Developed Immune Reconstitution Inflammatory Syndrome During ACTG A5164
Grant, P. M., Komarow, L., Lederman, M. M., Pahwa, S., Zolopa, A. R., Andersen, J., … Sereti, I. (2012). Elevated Interleukin 8 and T-Helper 1 and T-Helper 17 Cytokine Levels Prior to Antiretroviral Therapy in Participants Who Developed Immune Reconstitution Inflammatory Syndrome During ACTG A5164. JOURNAL OF INFECTIOUS DISEASES, 206(11), 1715–23. -
Early Antiretroviral Therapy for Patients With Acute AIDS-Related Opportunistic Infections: A Cost-Effectiveness Analysis of ACTG A5164
Sax, P. E., Sloan, C. E., Schackman, B. R., Grant, P. M., Rong, J., Zolopa, A. R., … Freedberg, K. A. (2010). Early Antiretroviral Therapy for Patients With Acute AIDS-Related Opportunistic Infections: A Cost-Effectiveness Analysis of ACTG A5164. HIV CLINICAL TRIALS, 11(5), 248–259. -
Blood (1 -> 3)-beta-D-Glucan as a Diagnostic Test for HIV-Related Pneumocystis jirovecii Pneumonia
Sax, P. E., Komarow, L., Finkelman, M. A., Grant, P. M., Andersen, J., Scully, E., … Zolopa, A. R. (2011). Blood (1 -> 3)-beta-D-Glucan as a Diagnostic Test for HIV-Related Pneumocystis jirovecii Pneumonia. CLINICAL INFECTIOUS DISEASES, 53(2), 197–202. -
Low Baseline CD4+ Count Is Associated With Greater Bone Mineral Density Loss After Antiretroviral Therapy Initiation.
Grant, P. M., Kitch, D., McComsey, G. A., Dube, M. P., Haubrich, R., Huang, J., … Brown, T. T. (2013). Low Baseline CD4+ Count Is Associated With Greater Bone Mineral Density Loss After Antiretroviral Therapy Initiation. Clinical Infectious Diseases , 57(10), 1483–88. -
TREATING PSYCHOLOGICAL TRAUMA AMONG RWANDAN ORPHANS IS ASSOCIATED WITH A REDUCTION IN HIV RISK-TAKING BEHAVIORS: A PILOT STUDY
Talbot, A., Uwihoreye, C., Kamen, C., Grant, P., McGlynn, L., Mugabe, I., … Zolopa, A. (2013). TREATING PSYCHOLOGICAL TRAUMA AMONG RWANDAN ORPHANS IS ASSOCIATED WITH A REDUCTION IN HIV RISK-TAKING BEHAVIORS: A PILOT STUDY. AIDS EDUCATION AND PREVENTION, 25(6), 468–79. -
Early Virologic Response to Abacavir/Lamivudine and Tenofovir/Emtricitabine During ACTG A5202
Grant, P. M., Tierney, C., Budhathoki, C., Daar, E. S., Sax, P. E., Collier, A. C., … Katzenstein, D. (2013). Early Virologic Response to Abacavir/Lamivudine and Tenofovir/Emtricitabine During ACTG A5202. HIV CLINICAL TRIALS, 14(6), 284–91. -
Comparative effectiveness and cost-effectiveness of antiretroviral therapy and pre-exposure prophylaxis for HIV prevention in South Africa.
Alistar, S. S., Grant, P. M., & Bendavid, E. (2014). Comparative effectiveness and cost-effectiveness of antiretroviral therapy and pre-exposure prophylaxis for HIV prevention in South Africa. BMC Medicine, 12, 46-? -
Evolution of HIV treatment guidelines in high- and low-income countries: Converging recommendations
Richardson, E. T., Grant, P. M., & Zolopa, A. R. (2014). Evolution of HIV treatment guidelines in high- and low-income countries: Converging recommendations. ANTIVIRAL RESEARCH, 103, 88–93. -
Association between Latent Proviral Characteristics and Immune Activation in Antiretrovirus-Treated Human Immunodeficiency Virus Type 1-Infected Adults.
Liang, E. C., Sceats, L., Bayless, N. L., Strauss-Albee, D. M., Kubo, J., Grant, P. M., … Blish, C. A. (2014). Association between Latent Proviral Characteristics and Immune Activation in Antiretrovirus-Treated Human Immunodeficiency Virus Type 1-Infected Adults. Journal of Virology, 88(15), 8629–39. -
Comparative effectiveness and cost-effectiveness of antiretroviral therapy and pre-exposure prophylaxis for HIV prevention in South Africa.
Alistar, S. S., Grant, P. M., & Bendavid, E. (2014). Comparative effectiveness and cost-effectiveness of antiretroviral therapy and pre-exposure prophylaxis for HIV prevention in South Africa. BMC Medicine, 12, 46-? -
Clinical and Immunologic Predictors of Death After an Acute Opportunistic Infection: Results from ACTG A5164
Grant, P. M., Komarow, L., Sanchez, A., Sattler, F. R., Asmuth, D. M., Pollard, R. B., & Zolopal, A. R. (2014). Clinical and Immunologic Predictors of Death After an Acute Opportunistic Infection: Results from ACTG A5164. HIV CLINICAL TRIALS, 15(4), 133–39. -
Encephalitis caused by chikungunya virus in a traveler from the kingdom of tonga.
Nelson, J., Waggoner, J. J., Sahoo, M. K., Grant, P. M., & Pinsky, B. A. (2014). Encephalitis caused by chikungunya virus in a traveler from the kingdom of tonga. Journal of Clinical Microbiology, 52(9), 3459–61. -
Patterns of peripheral neuropathy in ART-na < ve patients initiating modern ART regimen
Lee, A. J., Bosch, R. J., Evans, S. R., Wu, K., Harrison, T., Grant, P., & Clifford, D. B. (2015). Patterns of peripheral neuropathy in ART-na < ve patients initiating modern ART regimen. JOURNAL OF NEUROVIROLOGY, 21(2), 210–18. -
Differential skeletal impact of tenofovir disoproxil fumarate in young versus old HIV-infected adults
Grant, P. M., Kitch, D., McComsey, G. A., Tierney, C., Ha, B., & Brown, T. T. (2015). Differential skeletal impact of tenofovir disoproxil fumarate in young versus old HIV-infected adults. HIV CLINICAL TRIALS, 16(2), 66–71. -
Case Report: Molecular Detection of Leptospira in Two Returned Travelers: Higher Bacterial Load in Cerebrospinal Fluid versus Serum or Plasma
Waggoner, J. J., Soda, E. A., Seibert, R., Grant, P., & Pinsky, B. A. (2015). Case Report: Molecular Detection of Leptospira in Two Returned Travelers: Higher Bacterial Load in Cerebrospinal Fluid versus Serum or Plasma. AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 93(2), 238–40. -
Molecular Detection of Leptospira in Two Returned Travelers: Higher Bacterial Load in Cerebrospinal Fluid Versus Serum or Plasma.
Waggoner, J. J., Soda, E. A., Seibert, R., Grant, P., & Pinsky, B. A. (2015). Molecular Detection of Leptospira in Two Returned Travelers: Higher Bacterial Load in Cerebrospinal Fluid Versus Serum or Plasma. American Journal of Tropical Medicine and Hygiene, 93(2), 238–40. -
Modifying Antiretroviral Therapy in Virologically Suppressed HIV-1-Infected Patients
Collins, S. E., Grant, P. M., & Shafer, R. W. (2016). Modifying Antiretroviral Therapy in Virologically Suppressed HIV-1-Infected Patients. DRUGS, 76(1), 75–98. -
Clinically Indicated Corticosteroids Do Not Affect Bone Turnover During Immune Restoration of Severely Lymphopenic HIV-Infected Patients
Grant, P. M., Sheikh, V., DerSimonian, R., Rupert, A., Roby, G., Pau, A., … Sereti, I. (2015). Clinically Indicated Corticosteroids Do Not Affect Bone Turnover During Immune Restoration of Severely Lymphopenic HIV-Infected Patients. AIDS RESEARCH AND HUMAN RETROVIRUSES, 31(7), 739–44. -
Tenofovir and bone health
Grant, P. M., & Cotter, A. G. (2016). Tenofovir and bone health. CURRENT OPINION IN HIV AND AIDS, 11(3), 326–32. -
When to Start ART in the Setting of Acute AIDS-Related Opportunistic Infections: The Time Is Now!
Grant, P. M., & Zolopa, A. R. (2012). When to Start ART in the Setting of Acute AIDS-Related Opportunistic Infections: The Time Is Now! CURRENT HIV/AIDS REPORTS, 9(3), 251–258. -
Long-term Bone Mineral Density Changes in Antiretroviral-Treated HIV-Infected Individuals
Grant, P. M., Kitch, D., McComsey, G. A., Collier, A. C., Koletar, S. L., Erlandson, K. M., … Brown, T. T. (2016). Long-term Bone Mineral Density Changes in Antiretroviral-Treated HIV-Infected Individuals. JOURNAL OF INFECTIOUS DISEASES, 214(4), 607–11. -
A Randomized Switch From Nevirapine-Based Antiretroviral Therapy to Single Tablet Rilpivirine/Emtricitabine/Tenofovir Disoproxil Fumarate in Virologically Suppressed Human Immunodeficiency Virus-1-Infected Rwandans.
Collins, S. E., Grant, P. M., Uwinkindi, F., Talbot, A., Seruyange, E., Slamowitz, D., … Nsanzimana, S. (2016). A Randomized Switch From Nevirapine-Based Antiretroviral Therapy to Single Tablet Rilpivirine/Emtricitabine/Tenofovir Disoproxil Fumarate in Virologically Suppressed Human Immunodeficiency Virus-1-Infected Rwandans. Open Forum Infectious Diseases, 3(3), ofw141-? -
Long-term body composition changes in antiretroviral-treated HIV-infected individuals
Grant, P. M., Kitch, D., McComsey, G. A., Collier, A. C., Bartali, B., Koletar, S. L., … Brown, T. T. (2016). Long-term body composition changes in antiretroviral-treated HIV-infected individuals. AIDS, 30(18), 2805–13. -
Collaborative update of a rule-based expert system for HIV-1 genotypic resistance test interpretation.
Paredes, R., Tzou, P. L., van Zyl, G., Barrow, G., Camacho, R., Carmona, S., … Shafer, R. W. (2017). Collaborative update of a rule-based expert system for HIV-1 genotypic resistance test interpretation. PloS One, 12(7), e0181357. -
High Rates of Rapid Virologic Response for Chronic Hepatitis C Infection Treated with Ledipasvir/Sofosbuvir in Rwanda: Preliminary Results from the SHARED Study
Gupta, N., Kabahizi, J., Muvunyi, C., Mbituyumuremyi, A., Van Nuil, J. I., & Grant, P. M. (2017). High Rates of Rapid Virologic Response for Chronic Hepatitis C Infection Treated with Ledipasvir/Sofosbuvir in Rwanda: Preliminary Results from the SHARED Study. HEPATOLOGY, 66, 615A. -
Effect of Testosterone Use on Bone Mineral Density in HIV-infected Men.
Grant, P. M., Li, X., Jacobson, L., Palella, F. J., Kingsley, L., Margolick, J. B., … Brown, T. (2018). Effect of Testosterone Use on Bone Mineral Density in HIV-infected Men. AIDS Research and Human Retroviruses. -
Safety and Efficacy of Ledipasvir/Sofosbuvir without on-Treatment Laboratory Monitoring in HCV-Infected Rwandans: The Shared 2 Study
Grant, P., Kabahizi, J., Mbituyumuremyi, A., Van Nuil, J. I., Mukabatsinda, C., Damascene, M. J., … Gupta, N. (2018). Safety and Efficacy of Ledipasvir/Sofosbuvir without on-Treatment Laboratory Monitoring in HCV-Infected Rwandans: The Shared 2 Study. HEPATOLOGY, 68, 36A. -
A Comparison of the Liver Fat Score and CT Liver-to-Spleen Ratio as Predictors of Fatty Liver Disease by HIV Serostatus.
Mellor-Crummey, L. E., Lake, J. E., Wilhalme, H., Tseng, C.-H., Grant, P. M., Erlandson, K. M., … Brown, T. T. (2018). A Comparison of the Liver Fat Score and CT Liver-to-Spleen Ratio as Predictors of Fatty Liver Disease by HIV Serostatus. Journal of Clinical Gastroenterology and Hepatology, 2(3). -
Treatment of chronic hepatitis C virus infection in Rwanda with ledipasvir-sofosbuvir (SHARED): a single-arm trial.
Gupta, N., Mbituyumuremyi, A., Kabahizi, J., Ntaganda, F., Muvunyi, C. M., Shumbusho, F., … Grant, P. M. (2018). Treatment of chronic hepatitis C virus infection in Rwanda with ledipasvir-sofosbuvir (SHARED): a single-arm trial. The Lancet. Gastroenterology & Hepatology. -
Modifying Antiretroviral Therapy in Virologically Suppressed HIV-1-Infected Patients.
Collins, S. E., Grant, P. M., & Shafer, R. W. (2016). Modifying Antiretroviral Therapy in Virologically Suppressed HIV-1-Infected Patients. Drugs, 76(1), 75–98. -
Effect of Testosterone Use on Bone Mineral Density in HIV-Infected Men
Grant, P. M., Li, X., Jacobson, L. P., Palella, F. J., Kingsley, L. A., Margolick, J. B., … Brown, T. T. (2019). Effect of Testosterone Use on Bone Mineral Density in HIV-Infected Men. AIDS RESEARCH AND HUMAN RETROVIRUSES, 35(1), 75–80. -
A systematic review of the genetic mechanisms of dolutegravir resistance.
Rhee, S.-Y. Y., Grant, P. M., Tzou, P. L., Barrow, G., Harrigan, P. R., Ioannidis, J. P., & Shafer, R. W. (2019). A systematic review of the genetic mechanisms of dolutegravir resistance. The Journal of Antimicrobial Chemotherapy. -
Safety and Efficacy of Limited Laboratory Monitoring for Hepatitis C Treatment: A Blinded Clinical Trial in Rwanda
Grant, P., Shumbusho, F., Van Nuil, J. I., Kateera, F., Mukherjee, J., Kabahizi, J., … Gupta, N. (2020). Safety and Efficacy of Limited Laboratory Monitoring for Hepatitis C Treatment: A Blinded Clinical Trial in Rwanda. HEPATOLOGY COMMUNICATIONS. -
Safety and Efficacy of Limited Laboratory Monitoring for Hepatitis C Treatment: A Blinded Clinical Trial in Rwanda.
Grant, P., Shumbusho, F., Van Nuil, J. I., Kateera, F., Mukherjee, J., Kabahizi, J., … Gupta, N. (2020). Safety and Efficacy of Limited Laboratory Monitoring for Hepatitis C Treatment: A Blinded Clinical Trial in Rwanda. Hepatology Communications, 4(4), 569–576. -
Enhancing natural killer cell function with gp41-targeting bispecific antibodies to combat HIV infection.
Ramadoss, N. S., Zhao, N. Q., Richardson, B. A., Grant, P. M., Kim, P. S., & Blish, C. A. (2020). Enhancing natural killer cell function with gp41-targeting bispecific antibodies to combat HIV infection. AIDS (London, England). -
Remdesivir for 5 or 10 Days in Patients with Severe Covid-19.
Goldman, J. D., Lye, D. C., Hui, D. S., Marks, K. M., Bruno, R., Montejano, R., … Subramanian, A. (2020). Remdesivir for 5 or 10 Days in Patients with Severe Covid-19. The New England Journal of Medicine. -
Treated HIV Infection Alters Phenotype but Not HIV-Specific Function of Peripheral Blood Natural Killer Cells.
Zhao, N. Q., Ferreira, A.-M., Grant, P. M., Holmes, S., & Blish, C. A. (2020). Treated HIV Infection Alters Phenotype but Not HIV-Specific Function of Peripheral Blood Natural Killer Cells. Frontiers in Immunology, 11, 829. -
A single-cell atlas of the peripheral immune response in patients with severe COVID-19.
Wilk, A. J., Rustagi, A., Zhao, N. Q., Roque, J., Martinez-Colon, G. J., McKechnie, J. L., … Blish, C. A. (2020). A single-cell atlas of the peripheral immune response in patients with severe COVID-19. Nature Medicine. -
Cytokine profile in plasma of severe COVID-19 does not differ from ARDS and sepsis.
Wilson, J. G., Simpson, L. J., Ferreira, A.-M., Rustagi, A., Roque, J. A., Asuni, A., … Rogers, A. J. (2020). Cytokine profile in plasma of severe COVID-19 does not differ from ARDS and sepsis. JCI Insight. -
Use of Remdesivir for Pregnant Patients with Severe Novel 2019 Coronavirus Disease.
Igbinosa, I., Miller, S., Bianco, K., Nelson, J., Kappagoda, S., Blackburn, B. G., … Aziz, N. (2020). Use of Remdesivir for Pregnant Patients with Severe Novel 2019 Coronavirus Disease. American Journal of Obstetrics and Gynecology. -
Improved quality of life following direct-acting antiviral treatment for chronic hepatitis C infection in Rwanda: Results from a clinical trial in sub-Saharan Africa (the SHARED study).
Van Nuil, J. I., Umutesi, G., Shumbusho, F., Kateera, F., Dushimimana, J. de D., Muvunyi, C. M., … Gupta, N. (2020). Improved quality of life following direct-acting antiviral treatment for chronic hepatitis C infection in Rwanda: Results from a clinical trial in sub-Saharan Africa (the SHARED study). Journal of Viral Hepatitis. -
Risk factors for difficult-to-treat Hepatitis C Virus genotype 4r in Rwanda and implications for elimination in sub-Saharan africa.
Shumbusho, F., Liu, A. F., Kateera, F., Kabahizi, J., Nsanzaimana, S., Serumondo, J., … Gupta, N. (2021). Risk factors for difficult-to-treat Hepatitis C Virus genotype 4r in Rwanda and implications for elimination in sub-Saharan africa. Journal of Viral Hepatitis. -
A single-cell atlas of the peripheral immune response to severe COVID-19.
Wilk, A. J., Rustagi, A., Zhao, N. Q., Roque, J., Martinez-Colon, G. J., McKechnie, J. L., … Blish, C. A. (2020). A single-cell atlas of the peripheral immune response to severe COVID-19. MedRxiv : the Preprint Server for Health Sciences. -
Patients with uncomplicated COVID-19 have long-term persistent symptoms and functional impairment similar to patients with severe COVID-19: a cautionary tale during a global pandemic.
Jacobson, K. B., Rao, M., Bonilla, H., Subramanian, A., Hack, I., Madrigal, M., … Grant, P. (2021). Patients with uncomplicated COVID-19 have long-term persistent symptoms and functional impairment similar to patients with severe COVID-19: a cautionary tale during a global pandemic. Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America. -
Signatures of immune dysfunction in HIV and HCV infection share features with chronic inflammation in aging and persist after viral reduction or elimination.
Lopez Angel, C. J., Pham, E. A., Du, H., Vallania, F., Fram, B. J., Perez, K., … Furman, D. (2021). Signatures of immune dysfunction in HIV and HCV infection share features with chronic inflammation in aging and persist after viral reduction or elimination. Proceedings of the National Academy of Sciences of the United States of America, 118(14). -
SARS-CoV-2 Neutralization Resistance Mutations in Patient with HIV/AIDS, California, USA.
Hoffman, S. A., Costales, C., Sahoo, M. K., Palanisamy, S., Yamamoto, F., Huang, C. H., … Pinsky, B. A. (2021). SARS-CoV-2 Neutralization Resistance Mutations in Patient with HIV/AIDS, California, USA. Emerging Infectious Diseases, 27(10). -
Factors Associated with Resilience Among Older People Living with HIV.
Berko, J., Mazonson, P., Loo, T., Grant, P., Zolopa, A., Spinelli, F., & Short, D. (2021). Factors Associated with Resilience Among Older People Living with HIV. AIDS and Behavior. -
Fostemsavir: a first-in-class HIV-1 attachment inhibitor.
Grant, P. M., & Kozal, M. J. (2022). Fostemsavir: a first-in-class HIV-1 attachment inhibitor. Current Opinion in HIV and AIDS, 17(1), 32–35. -
Survivors of SARS-CoV-2 Infection Show Neuropsychiatric Sequelae Measured by Surveys, Neurocognitive Testing, and Magnetic Resonance Imaging: Preliminary Results
Hack, L., Brawer, J., Zhang, X., Wintermark, M., Jiang, B., Stetz, P., … Williams, L. (2021). Survivors of SARS-CoV-2 Infection Show Neuropsychiatric Sequelae Measured by Surveys, Neurocognitive Testing, and Magnetic Resonance Imaging: Preliminary Results. NEUROPSYCHOPHARMACOLOGY. SPRINGERNATURE. -
Safety and efficacy of sofosbuvir-velpatasvir to treat chronic hepatitis C virus infection in treatment-naive patients in Rwanda (SHARED-3): a single-arm trial.
Kateera, F., Shumbusho, F., Manirambona, L., Kabihizi, J., Murangwa, A., Serumondo, J., … Gupta, N. (2022). Safety and efficacy of sofosbuvir-velpatasvir to treat chronic hepatitis C virus infection in treatment-naive patients in Rwanda (SHARED-3): a single-arm trial. The Lancet. Gastroenterology & Hepatology. -
Safety and efficacy of sofosbuvir-velpatasvir-voxilaprevir for re-treatment of chronic hepatitis C virus infection in patients with previous direct-acting antiviral treatment failure in Rwanda (SHARED-3): a single-arm trial.
Gupta, N., Manirambona, L., Shumbusho, F., Kabihizi, J., Murangwa, A., Serumondo, J., … Kateera, F. (2022). Safety and efficacy of sofosbuvir-velpatasvir-voxilaprevir for re-treatment of chronic hepatitis C virus infection in patients with previous direct-acting antiviral treatment failure in Rwanda (SHARED-3): a single-arm trial. The Lancet. Gastroenterology & Hepatology. -
Associations between county-level public health expenditures and community health planning activities with COVID-19 incidence and mortality.
Liang, R., Kiang, M. V., Grant, P., Jackson, C., & Rehkopf, D. H. (2023). Associations between county-level public health expenditures and community health planning activities with COVID-19 incidence and mortality. Preventive Medicine Reports, 36, 102410. -
Prevalence of Emergent Dolutegravir Resistance Mutations in People Living with HIV: A Rapid Scoping Review.
Chu, C., Tao, K., Kouamou, V., Avalos, A., Scott, J., Grant, P. M., … Shafer, R. W. (2024). Prevalence of Emergent Dolutegravir Resistance Mutations in People Living with HIV: A Rapid Scoping Review. Viruses, 16(3). -
Sex differences and immune correlates of Long COVID development, persistence, and resolution.
Hamlin, R. E., Pienkos, S. M., Chan, L., Stabile, M. A., Pinedo, K., Rao, M., … Blish, C. A. (2024). Sex differences and immune correlates of Long COVID development, persistence, and resolution. BioRxiv : the Preprint Server for Biology. -
Sex differences and immune correlates of Long Covid development, symptom persistence, and resolution.
Hamlin, R. E., Pienkos, S. M., Chan, L., Stabile, M. A., Pinedo, K., Rao, M., … Blish, C. A. (2024). Sex differences and immune correlates of Long Covid development, symptom persistence, and resolution. Science Translational Medicine, 16(773), eadr1032. -
Age-dependent cytokine surge in blood precedes cancer diagnosis.
Chen, G., Mohsin, A., Zheng, H., Rosenberg-Hasson, Y., Padilla, C., Sarin, K. Y., … Davis, M. M. (2025). Age-dependent cytokine surge in blood precedes cancer diagnosis. Proceedings of the National Academy of Sciences of the United States of America, 122(12), e2420502122.
-
Initiation of antiretroviral therapy in the hospitalized patient with an acute AIDS-related opportunistic infection and other conditions: no time to lose.
Clinical Trials
Clinical trials are ÌÇÐÄ´«Ã½ studies that evaluate a new medical approach, device, drug, or other treatment. As a ÌÇÐÄ´«Ã½ patient, you may have access to the latest, advanced clinical trials.
Open trials refer to studies currently accepting participants. Closed trials are not currently enrolling, but may open in the future.
- Study to Evaluate the Safety and Efficacy of Stribild Versus Ritonavir-Boosted Atazanavir Plus Truvada in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults
- High Dose Vitamin D and Calcium for Bone Health in Individuals Initiating HAART
- D/C/F/TAF Versus COBI-boosted DRV Plus FTC/TDF in HIV-1 Infected, Antiretroviral Treatment Naive Adults
- Stanford Universities: The Stanford HIV Aging Cohort
- The Effects of Attenuated Versus Inactivated Flu Vaccine in Twin Sets
- A Study to Treat Subjects With Telaprevir, Ribavirin, and Peginterferon Who Are Coinfected With HIV and Hepatitis C Virus (HCV)
- Evaluating the Effectiveness of Boceprevir, Pegylated-Interferon Alfa 2b and Ribavirin in Treating Hepatitis C Virus (HCV) Infection in Adults With HIV and HCV Infection
- Safety of and Immune Response to an Investigational HIV-1 Vaccine With or Without Interleukin-12 (IL-12) in HIV-1 Infected Adults
Practice Locations
Positive Care Clinic Palo Alto, CA
Palo Alto, CA
Positive Care Clinic
211 Quarry Rd
Palo Alto , CA 94304
Make An Appointment More Clinic Information Getting HereImportant Information about Our Organizations and Physician Affiliation
ÌÇÐÄ´«Ã½, ÌÇÐÄ´«Ã½ Tri-Valley, and Stanford Medicine Partners are each independent nonprofit organizations that are affiliated with but separate from each other and from Stanford University. The physicians who provide care at facilities operated by ÌÇÐÄ´«Ã½, ÌÇÐÄ´«Ã½ Tri-Valley, and Stanford Medicine Partners are faculty, foundation, or community physicians who are not employees, representatives, or agents of ÌÇÐÄ´«Ã½, ÌÇÐÄ´«Ã½ Tri- Valley, or Stanford Medicine Partners. ÌÇÐÄ´«Ã½, ÌÇÐÄ´«Ã½ Tri-Valley, and Stanford Medicine Partners do not exercise control over the care provided by such faculty, foundation, and community physicians and are not responsible for their actions.
Patient Reviews
(34 reviews)
Highly recommended clinic.
Dr. Grant has excellent bedside manner. He is top of his game professionally.
Good.
They are good to me.
This was important visit because of medication changes. Good discussion about why drugs were being changed.
Dr. Grant is an excellent doctor.
Dr. Grant is extremely easy to talk to, and never hurries through appointment or discussions - very thorough
Thank you Dr. Philip Grant.
Dr. Grant has always been a caring and attentive doctor. Very happy I am his patient.
Dr. Grant is a good doctor. He always care and listens. Excellent.
Dr. Grant was on the phone as he is in the office: very professional, very personable and thorough in performing a medical investigation and patient counselling.
Dr. Grant is very smart; he works with you to develop your own wellness approach to life; he is empathetic
this care provider did a good job with the device I brought and the wort froze successfully. He also prescribed pain medication I needed. He should be commended on a job well thought out.
Dr. Grant is one of a few truly compassionate doctors of any discipline I've ever had the pleasure of being a patient.
Good.
He seemed much more concerned about minutia, his clinic's integrity, & standard operating procedure than my unique concerns given my case is very complex & multidisciplinary.
Always courteous and replies/responds to my online communication through MyHealth platform.
Dr. Grant is awesome! A real plus to Stanford.
Stanford positive care is best.
THe dr. showed a great deal of empathy, perceptiveness and professionalism. He was very easy to speak to and he seemed to really care. I would highly recommend him to others.
I was seen on the same day as I called. No complaints there. Very grateful.
Dr. Grant is excellent in all regards.
I would like it if they send me or order me more punctual medications to the pharmacy so I won't miss a day since for me it is very important to take my medications.
Everything was good.
All excellent.
I think it takes time for Dr. Grant to get to know patients, and now we have a very good dr./patient relationship.
The doctor took great care to answer all my questions in detail, and was very friendly -
Eased some concerns and answered questions that my prior IDC doctor didn't do.
Love love love Dr Grant, his staff, and Stanford Medical!!
Dr. Grant is quite effective.
Dr. Grant is like a friend. I was shocked when he remembered so much about me and my personal life.
I drive 5 hours to see Dr. Grant. He and his staff are awesome.
The service and care was the best!
I really feel like I've won the lottery having such a wonderful dr. such as Dr. Grant. He is warm, attentive and helpful.
View More Patient Reviews
Referring Physicians
PHYSICIAN HELPLINE
Phone:Ìý1-866-742-4811
Fax: 650-320-9443
Monday–Friday, 8 a.m.–5 p.m.
Fax: 650-320-9443
Monday–Friday, 8 a.m.–5 p.m.
ÌÇÐÄ´«Ã½ provides comprehensive services toÌýreferÌýandÌýtrack patients, as well as the latest information and news for physicians and office staff.ÌýFor help with all referral needs and questions, visit Referral Information.
You may also submit a web referral or complete a referral form and fax it to 650-320-9443 or email the Referral Center at ReferralCenter@stanfordhealthcare.org.
Ìý
- Send referrals online
- Place radiology and lab orders
- View referral status
- Access medical records